In preclinical studies, first-generation anti-oxMIF antibodies (BaxB01, BaxG03, BaxM159) neutralized some of the key tumor-promoting activities attributed to MIF in vitro and in vivo [18], and were able to detect oxMIF in primary tumors and metastases of different solid tumors [15]. The gene discussed is MIF; the disease is neoplasm.